» Articles » PMID: 9353593

1H NMR Ganglioside Ceramide Resonance Region on the Differential Diagnosis of Low and High Malignancy of Brain Gliomas

Abstract

1. The high-resolution 1H NMR (MRS) spectra of human brain tumor homogenates revealed a broad resonance at 5.3-5.4 ppm in glioblastoma multiforme (N = 16) and brain metastases (N = 3). The broad resonance was identified as ceramide, a sphingosine-fatty acid combination portion of ganglioside, indicating an elevated abundance of monounsaturated fatty acids. GLC analysis of gangliosides in the highly malignant glioblastoma multiforme revealed that the elevated monounsaturated fatty acid is oleic acid (C18:1). The resonance at 5.3-5.4 ppm region was not detectable in normal human brain (N = 2), in meningiomas (N = 2), or in low-grade astrocytomas (N = 12). In normal human brain the abundance of monounsaturated fatty acid is minimal. 2. This investigation was made possible because the method of producing homogenate resulted in (i) no loss of lipids during the process and (ii) a well-homogenised sample, with (iii) no loss in chemical integrity. 3. The properties of tumor gangliosides include antigenic specificity and immunosuppressive activity and the ceramide, a sphingosine-fatty acid combination, noticeably influences the ganglioside immunosuppressive activity. 4. The observation of 1H NMR ceramide resonance in high-malignant brain tumors emphasizes the dramatic role of aberant gangliosides and ceramide precursors on the grade of malignancy and invasiveness. 5. Further insight into the specific nature of the ceramide portion of gangliosides in grading the malignancy of brain tumors should be investigated further.

Citing Articles

Proton MRS imaging in pediatric brain tumors.

Zarifi M, Tzika A Pediatr Radiol. 2016; 46(7):952-62.

PMID: 27233788 DOI: 10.1007/s00247-016-3547-5.


Use of in vivo two-dimensional MR spectroscopy to compare the biochemistry of the human brain to that of glioblastoma.

Ramadan S, Andronesi O, Stanwell P, Lin A, Sorensen A, Mountford C Radiology. 2011; 259(2):540-9.

PMID: 21357517 PMC: 3079117. DOI: 10.1148/radiol.11101123.

References
1.
Valentino L, Ladisch S . Localization of shed human tumor gangliosides: association with serum lipoproteins. Cancer Res. 1992; 52(4):810-4. View

2.
Wikstrand C, Longee D, McLendon R, Fuller G, Friedman H, Fredman P . Lactotetraose series ganglioside 3',6'-isoLD1 in tumors of central nervous and other systems in vitro and in vivo. Cancer Res. 1993; 53(1):120-6. View

3.
Remy C, Arus C, Ziegler A, Lai E, Moreno A, Le Fur Y . In vivo, ex vivo, and in vitro one- and two-dimensional nuclear magnetic resonance spectroscopy of an intracerebral glioma in rat brain: assignment of resonances. J Neurochem. 1994; 62(1):166-79. DOI: 10.1046/j.1471-4159.1994.62010166.x. View

4.
Wikstrand C, Fredman P, Svennerholm L, Bigner D . Detection of glioma-associated gangliosides GM2, GD2, GD3, 3'-isoLM1 3',6'-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies. Prog Brain Res. 1994; 101:213-23. DOI: 10.1016/s0079-6123(08)61951-2. View

5.
Kitagawa H, Nakada H, Fukui S, Funakoshi I, Kawasaki T, Tate S . Novel gangliosides containing the sialyl-Le(a) structure from a human rectal adenocarcinoma. J Biol Chem. 1993; 268(35):26541-5. View